JP2023522644A - プレウロムチリンの治療的使用 - Google Patents

プレウロムチリンの治療的使用 Download PDF

Info

Publication number
JP2023522644A
JP2023522644A JP2022562465A JP2022562465A JP2023522644A JP 2023522644 A JP2023522644 A JP 2023522644A JP 2022562465 A JP2022562465 A JP 2022562465A JP 2022562465 A JP2022562465 A JP 2022562465A JP 2023522644 A JP2023522644 A JP 2023522644A
Authority
JP
Japan
Prior art keywords
hydroxy
acetyl
cyclohexylsulfanyl
mutilin
diastereomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522644A5 (https=
JPWO2021209174A5 (https=
Inventor
ハフナー、マイケル
パオクナー、シュザンヌ
ヴィッカ、ヴォルフガング
リーデル、ローズマリー
－ シェーンフェルト、ズリンカ イヴェジック
Original Assignee
ナブリバ セラピューティクス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナブリバ セラピューティクス ゲーエムベーハー filed Critical ナブリバ セラピューティクス ゲーエムベーハー
Publication of JP2023522644A publication Critical patent/JP2023522644A/ja
Publication of JP2023522644A5 publication Critical patent/JP2023522644A5/ja
Publication of JPWO2021209174A5 publication Critical patent/JPWO2021209174A5/ja
Priority to JP2025230606A priority Critical patent/JP2026041886A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/16—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022562465A 2020-04-17 2021-04-16 プレウロムチリンの治療的使用 Pending JP2023522644A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025230606A JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011474P 2020-04-17 2020-04-17
EP20170072.1 2020-04-17
US63/011,474 2020-04-17
EP20170072 2020-04-17
EP20183292.0 2020-06-30
EP20183292 2020-06-30
PCT/EP2021/025140 WO2021209174A1 (en) 2020-04-17 2021-04-16 Therapeutic use of pleuromutilins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025230606A Division JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Publications (3)

Publication Number Publication Date
JP2023522644A true JP2023522644A (ja) 2023-05-31
JP2023522644A5 JP2023522644A5 (https=) 2025-07-30
JPWO2021209174A5 JPWO2021209174A5 (https=) 2025-07-30

Family

ID=75801547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562465A Pending JP2023522644A (ja) 2020-04-17 2021-04-16 プレウロムチリンの治療的使用
JP2025230606A Pending JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025230606A Pending JP2026041886A (ja) 2020-04-17 2025-12-04 プレウロムチリンの治療的使用

Country Status (9)

Country Link
US (1) US20230174472A1 (https=)
EP (1) EP4135682A1 (https=)
JP (2) JP2023522644A (https=)
CN (1) CN115443131A (https=)
BR (1) BR112022020007A2 (https=)
CA (1) CA3180535A1 (https=)
IL (1) IL297268A (https=)
TW (1) TW202203908A (https=)
WO (1) WO2021209174A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250134844A1 (en) 2022-02-09 2025-05-01 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia
CN119925362A (zh) * 2023-11-03 2025-05-06 阳光安津(南京)生物医药科技有限公司 一种化合物在制备用于治疗银屑病的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522143A (ja) * 2007-03-20 2010-07-01 ナブリヴァ セラピュティクス アクチエンゲゼルシャフト 微生物によって媒介される病気の治療のためのプレウロムチリン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0803707D0 (en) 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103242210B (zh) 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
KR102656841B1 (ko) 2015-06-17 2024-04-12 나브리바 테라퓨틱스 게엠베하 레파뮬린의 주사가능한 약제학적 제형
CN110507823B (zh) * 2019-08-20 2021-08-24 中国医学科学院基础医学研究所 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522143A (ja) * 2007-03-20 2010-07-01 ナブリヴァ セラピュティクス アクチエンゲゼルシャフト 微生物によって媒介される病気の治療のためのプレウロムチリン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INFLAMMATION, vol. 33, no. 5, JPN6025007170, 2010, pages 306 - 311, ISSN: 0005800073 *

Also Published As

Publication number Publication date
CA3180535A1 (en) 2021-10-21
IL297268A (en) 2022-12-01
BR112022020007A2 (pt) 2022-11-22
WO2021209174A1 (en) 2021-10-21
EP4135682A1 (en) 2023-02-22
TW202203908A (zh) 2022-02-01
US20230174472A1 (en) 2023-06-08
CN115443131A (zh) 2022-12-06
JP2026041886A (ja) 2026-03-10

Similar Documents

Publication Publication Date Title
JP2026041886A (ja) プレウロムチリンの治療的使用
US12458622B2 (en) Methods of treatment of coronavirus-induced inflammation conditions
US20150110767A1 (en) Methods for treating lung infections and inflammation
CN115836079B (zh) 烟酰胺单核苷酸和烟酰胺核苷衍生物及其在治疗特别是由流感病毒或冠状病毒引起的病毒感染和呼吸道并发症中的用途
CN113304166B (zh) 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
EP4135683B1 (en) Antiviral use of pleuromutilins
JP2023529834A (ja) コロナウイルス感染症を治療する方法
KR20200010302A (ko) 세균 이차 감염의 치료 및/또는 예방에 사용하기 위한 il-8 억제제
WO2020241759A1 (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
CN115484953A (zh) 治疗细胞因子风暴综合症及相关疾病的方法
US20210236580A1 (en) Methods and Compositions for Mitigating Symptoms of Acute Respiratory Distress Syndrome
CA3187751A1 (en) Macrophage targeting drug conjugates
JP2023520917A (ja) 呼吸器状態を処置するためのｔｒｐｃ６阻害剤
MX2012005551A (es) Tratamiento de infecciones microbianas.
EP4346789B1 (en) Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
EP4135681B1 (en) Antiviral use of pleuromutilins
EP4125924B1 (en) Furosemide compositions for use in supportive therapy in coronavirus infection
CN113952457A (zh) 泰瑞米特或含有泰瑞米特的药物组合物在抗冠状病毒中的应用
JPH05310578A (ja) ミゾリビンを有効成分とする感染疾患の予防または治療剤
RU2845060C1 (ru) Нацеленные на макрофаги конъюгаты лекарственных средств
CN117085138A (zh) 一种提高免疫力和抗病原感染的组合物及其用途
WO2025257401A1 (en) Novel isophthalate compounds for the treatment of a viral lung infection
CN113304158A (zh) 磺胺甲氧吡嗪在制备预防和/或治疗牛副流感病毒产品中的应用
HK40089361A (zh) 巨噬细胞靶向的药物缀合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250521

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260417